Cannabinoids and Wake after sleep onset

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported fewer nighttime awakenings following 20 mg CBN over 7 nights. The recorded comparator was placebo. ¹

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported lower overall sleep disturbance following 20 mg CBN over 7 nights. The recorded comparator was placebo. ¹

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in sleep onset latency following 20 mg CBN over 7 nights. The recorded comparator was placebo. ¹

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in wake after sleep onset following 20 mg CBN over 7 nights. The recorded comparator was placebo. ¹

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in daytime fatigue following 20 mg CBN over 7 nights. The recorded comparator was placebo. ¹

In a double-blind randomized placebo-controlled multi-arm trial involving 293 adults with self-rated poor or very poor sleep quality, researchers did not detect a difference in augmentation of cbn sleep effects following 20 mg CBN with 10 mg, 20 mg, or 100 mg CBD nightly by the not stated in the PubMed abstract route over 7 nights. The recorded comparator was 20 mg CBN alone and placebo. ¹

Recorded result: Adding CBD did not positively augment the CBN treatment effects.

In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers reported a decrease in total sleep time after an acute THC-CBD dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. ²

Recorded result: Total sleep time decreased by 24.5 minutes (P=.05; d=-.5).

In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers did not detect a difference in subjective sleep quality after an acute thc-cbd dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. ²

Recorded result: No change in subjective sleep quality was detected.

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers did not detect a difference in self-reported sleep-onset latency following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ³

Recorded result: No between-treatment difference was detected throughout the trial (P>0.05).

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers did not detect a difference in self-reported sleep efficiency following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ³

Recorded result: No between-treatment difference was detected throughout the trial (P>0.05).

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers did not detect a difference in wake after sleep onset following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ³

Recorded result: No between-treatment difference was detected throughout the trial (P>0.05).

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers reported an increase in objective sleep efficiency following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ³

Recorded result: Mean difference 6.85 (standard error 2.95; P<0.05).

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers did not detect a difference in wake after sleep onset following a single oral dose of 30 mg or 300 mg CBN. The recorded comparator was placebo. ⁴

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported shorter sleep onset latency following 300 mg CBN. The recorded comparator was placebo. ⁴

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported higher subjective sleep quality following 300 mg CBN. The recorded comparator was placebo. ⁴

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported more NREM-2 sleep following 300 mg CBN. The recorded comparator was placebo. ⁴

In an exploratory prospective open-label trial involving 18 patients with restless legs syndrome, 16 with multiple sclerosis, researchers reported a decrease in wake after sleep onset in an open-label RLS study following 2.7 mg THC/2.5 mg CBD with titration at week 4 if required by the not stated in the PubMed abstract route over 3 months with observational one-year follow-up. The recorded comparator was none; baseline comparison. ⁵

Recorded result: WASO decreased from baseline (P=.015).

In an exploratory prospective open-label trial involving 18 patients with restless legs syndrome, 16 with multiple sclerosis, researchers did not detect a difference in sleep latency or sleep efficiency in an open-label rls study following 2.7 mg THC/2.5 mg CBD with titration at week 4 if required by the not stated in the PubMed abstract route over 3 months. The recorded comparator was none; baseline comparison. ⁵

Recorded result: No significant baseline-to-follow-up changes in sleep latency or sleep efficiency were detected.